|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 非诺贝特治疗与2型糖尿病患者长期心血管病风险的关系显示文摘2型糖尿病患者心血管病风险高,部分原因在于高三酰甘油和低高密度脂蛋白胆固醇血症。而在他汀类药物治疗基础上,加强降低三酰甘油治疗,能否降低这种风险尚不清楚。该研究的目的是在使用他汀类药物治疗的2型糖尿病患者中,确定非诺贝特能否降低心血管病风险。 | 刘莉 叶鹏 Elam MB Ginsberg HN Lovato LC Corson M Largay J Leiter LA Lopez C O'Connor PJ Sweeney ME Weiss D Friedewald WT Buse JB Gerstein HC Probstfield J Grimm R Ismail-Beigi F Goff DC Jr Fleg JL Rosenberg Y Byington RP ACCORDION study investigators | 2017 | 中华高血压杂志2017，25，6： | 7 |
| 2 | Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study显示文摘 | Daniel J Drucker John B Buse Kristin Taylor David M Kendall Michael Trautmann Dongliang Zhuang Lisa Porter | 2008 | The Lancet2008，，9645： | 2 |
| 3 | The metabolic syndrome:time for a criticaL appraisal:joint statement from the American Diabetes Association and the European Association for the Study of Diabetes 显示文摘 | Kahn R Buse J Ferrannini E | 2005 | Diabetes Care2005，28，9： | 1 |
| 4 | Fenofibrate -associ- ated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes : the Action to Control Car- diovascular Risk in Diabetes (ACCORD) experience 显示文摘 | BONDS D E CRAVEN T E BUSE J | 2012 | Diabe- tologia2012，55，6： | 1 |
| 5 | Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy显示文摘 | Nathan D M Buse J B Davidson M B | 2008 | Diabetologia2008，16，51： | 1 |
| 6 | Management of hyperglycemia in type 2 diabetes:a patient-centered approach:position statement of the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)显示文摘 | INZUCCHI S E BERGENSTAL R M BUSE J B | 2012 | Diabetes Care2012，35，6： | 1 |
| 7 | The effects of oral anti - hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes显示文摘 | BUSE J B TAN M H PRINCE M J | 2004 | Diabetes Obes Metab2004，6，2： | 1 |
| 8 | Management of hyperglycaemiain type 2 diabetes mellitus: a consensus algorithm for the initiation andadjustment oftherapy显示文摘 | Nathan D M Buse J B Davidson M B | 2008 | Diabetologia2008，51，1： | 1 |
| 9 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) 显示文摘 | Buse J B Rosenstock J Sesti G | 2009 | Lancet2009，374，9683： | 1 |
| 10 | Efficacy and safety of the humanglucagon-like peptide-1 analog liraglutide in combination with metformin andthiazolidinedione in patients with type 2 diabetes 显示文摘 | Zinman B Gerich J Buse JB | 2009 | Diabetes Care2009，32，： | 1 |
| 11 | Exenatide once weekly versus lira- glutide once daily in patients with type 2 diabetes (DURATION-6) : a randomised, open-label study显示文摘 | Buse J B Nauck M Forst T | 2013 | Lancet2013，381，9861： | 1 |
| 12 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomised,parallel-group,multinational,open-label trial(LEAD-6)显示文摘 | Buse JB Rosenstock J Sesti G | 2009 | Lancet2009，374，9683： | 1 |
| 13 | Impact of drinking water conditions and copper materials on downstream biofilm microbial communities and Legionella pneumophila colonization 显示文摘 | Lu J Buse HY Gomez-Alvarez V et at | 2014 | J Appl Microbiol2014，117，： | 1 |
| 14 | Effects of exenatide (exendin -4) on glycemic control over 30 weeks in sulfonylurea - treated patients with type 2 diabetes 显示文摘 | Buse JB Henry RR Hart J | 2004 | Diabetes Care2004，27，： | 1 |
| 15 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomized, parallel-group,multinational, open-label trial LEAD-6 显示文摘 | Buse J Rosenstock J Sesti G | 2009 | J Lancet2009，374，9683： | 1 |
| 16 | The metabolic syndrome for a critical appraisal:joint statement from the American Diabetes Association and the European Association for the Study of Diabetes 显示文摘 | Kahn R Buse J Ferrannini E | 2005 | Diabetes Care2005，28，9： | 1 |
| 17 | Neuromodulation in Tourette syndrome: dopamine and beyond显示文摘 | Buse J Schoenefeld K Mtinchau A | 2013 | Neurosci Biobehav Rev2013，37，6： | 1 |
| 18 | Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘 | KLONOFF D C BUSE J B NIELSEN L L | 2008 | Curr Med Res Opin2008，24，1： | 1 |
| 19 | Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation andadjustment of therapy a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes显示文摘 | Nathan D M Buse J B Davidson M B | 2009 | Diabetes care2009，32，1： | 1 |
| 20 | Action to con- trol cardiovascular risk in diabetes (ACCORD) trial : design and methods 显示文摘 | BUSE J B BIGGER J T BYINGTON R P | 2007 | Am J Cardiol2007，99，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员